Estrogen use should be discontinued unless its need outweighs its adverse effects on porphyrin metabolism. After achievement of remission, estrogen therapies may be cautiously reinstituted; however, the duration of remissions may be shortened. Plaquenil depressione Hydroxychloroquine urticarial vasculitis Can plaquenil and elavil be taken together If you have porphyria cutanea tarda, your treatment might include Regular removal of your blood to lower the amount of iron in your liver. This is called phlebotomy. Porphyria cutanea tarda commonly referred to as PCT is recognized as the most prevalent subtype of porphyritic diseases. The disease is characterized by onycholysis and blistering of the skin in areas that receive higher levels of exposure to sunlight. The primary cause of this disorder is a deficiency of uroporphyrinogen decarboxylase UROD, a cytosolic enzyme that is a step in the enzymatic pathway that leads to the synthesis of heme. Background &AimsPorphyria cutanea tarda PCT is an iron-related disorder caused by reduced activity of hepatic uroporphyrinogen decarboxylase; it can be treated by phlebotomy or low doses of hydroxychloroquine. If symptoms recur, re-treatment can restore remissions. Remissions may last from several months to many years. Why hydroxychloroquine for porphyria cutanea tarda Hydroxychloroquine - Wikipedia, Porphyria cutanea tarda - Wikipedia Will plaquenil treat lupus and rheumatoid arthritisUser reviews of plaquenilA drug that for rumatoid hydroxychloroquineChloroquine lysosomal membrane permeabilizationHow to bill for following plaquenil retina Arch Dermatol. 1980 Oct;116101147-50. Hydroxychloroquine treatment of porphyria cutanea tarda. Malkinson FD, Levitt L. Six patients with skin changes and urinary porphyrin excretion patterns characteristic for porphyria cutanea tarda were treated with hydroxychloroquine sulfate therapy. Hydroxychloroquine treatment of porphyria cutanea tarda.. Low-Dose Hydroxychloroquine Is as Effective as Phlebotomy in Treatment.. Porphyria cutanea tarda - Approach BMJ Best Practice. BACKGROUND & AIMS Porphyria cutanea tarda PCT is an iron-related disorder caused by reduced activity of hepatic uroporphyrinogen decarboxylase; it can be treated by phlebotomy or low doses of hydroxychloroquine. We performed a prospective pilot study to compare the efficacy and safety of these therapies. For porphyria cutanea tarda, hydroxychloroquine is used to absorb excess porphyrins in patients who cannot tolerate phlebotomy to reduce the body’s iron and porphyrins. Background High-dose hydroxychloroquine is rarely used in the treatment of porphyria cutanea tarda PCT. Objective The purpose of this study was to evaluate the efficacy and safety of a novel highdose hydroxychloroquine regimen in patients with PCT.